Advertisement

Melanoma pp 469-481 | Cite as

Desmoplastic Melanoma

  • Teresa A. Bailey
  • John F. Thompson
  • Richard A. ScolyerEmail author
Reference work entry

Abstract

Desmoplastic melanoma is a rare subtype of melanoma accounting for 1–4% of all melanomas. There are a number of clinical and pathological features that distinguish desmoplastic melanoma from conventional melanoma. Desmoplastic melanoma usually occurs in the elderly, particularly males, and on chronically sun-damaged skin, especially on the head and neck region. Lesions often present in an innocuous fashion, and are frequently unrecognized or misdiagnosed clinically. The pathological diagnosis of desmoplastic melanoma can also be very challenging, because the tumor is often very subtle and its morphological features overlap with nonneoplastic conditions such as scars, as well as benign and malignant neoplasms. Histologically, desmoplastic melanoma is characterized by malignant spindle cells in which individual tumor cells are separated by collagen fibers. There are two subtypes of desmoplastic melanoma, namely pure and mixed. In the pure subtype, the overwhelming majority of invasive tumor is desmoplastic, while in the mixed subtype (which may consist of spindled or epithelioid cells, or both), the desmoplastic areas account for less than 90% of the invasive tumor. Desmoplastic melanoma has an affinity for nerves and a propensity for local recurrence. Compared with other melanoma subtypes, desmoplastic melanoma more frequently metastasizes to the lungs and less frequently to lymph nodes. The molecular landscape of desmoplastic melanoma is quite different from that of conventional melanoma; it has a higher mutation rate and almost always lacks BRAF, NRAS, or KIT mutations, commonly present in other subtypes. Recent genomic studies have highlighted the very high DNA mutation load of desmoplastic melanoma and clinical studies suggest patients with metastatic desmoplastic melanoma have higher response rates to immunotherapy. Primary desmoplastic melanoma should be treated by wide local excision of the primary tumor. The role of sentinel lymph node biopsy in patients with desmoplastic melanoma is controversial; a number of early studies showed the rate of sentinel lymph node metastasis in patients with pure subtype desmoplastic melanoma was very low (approximately 1%), while much higher rates have been reported in more recent studies.

Keywords

Desmoplastic Spindle cell Neurotropism Sentinel lymph node 

Notes

Acknowledgements

R.A.S. is supported by the National Health and Medical Research Council of Australia. J.F.T. is supported by the Melanoma Foundation of the University of Sydney. T.A.B.. is supported by a Melanoma Institute Australia Fellowship funded by Deborah and John McMurtrie.

References

  1. Chen JY, Hruby G, Scolyer RA, Murali R, Hong A, FitzGerald P, Pham TT, Quinn M, Thompson JF (2008) Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 113(10): 2770–2777.  https://doi.org/10.1002/cncr.23895CrossRefPubMedGoogle Scholar
  2. Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA (2013) Desmoplastic melanoma: a review. J Am Acad Dermatol 68(5):825–833.  https://doi.org/10.1016/j.jaad.2012.10.041CrossRefPubMedGoogle Scholar
  3. Dunne JA, Wormald JCR, Steele J, Woods E, Odili J, Powell BWEM (2017) Is sentinel lymph node biopsy warranted for desmoplastic melanoma? A systematic review. J Plast Reconstr Aesthet Surg 70:274–280CrossRefGoogle Scholar
  4. Eroglu Z, Zaretsky J, Hu-Lieskovan S, Kim D, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553(7688):347–350.  https://doi.org/10.1038/nature25187CrossRefPubMedPubMedCentralGoogle Scholar
  5. Gyorki DE, Busam K, Panageas K, Brady MS, Coit DG (2003) Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 10(4):403–407.  https://doi.org/10.1245/ASO.2003.04.003CrossRefPubMedGoogle Scholar
  6. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545(7653):175–180.  https://doi.org/10.1038/nature22071CrossRefPubMedGoogle Scholar
  7. Hunter Shain A, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, Chung J, Wang NJ, Kakavand H, Mann GJ, Thompson JF, Wiesner T, Roy R, Olshen AB, Gagnon A, Gray JW, Huh N, Hur JS, Busam KJ, Scolyer RA, Cho RJ, Murali R, Bastian BC (2015) Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 47(10):1194–1199.  https://doi.org/10.1038/ng.3382CrossRefPubMedPubMedCentralGoogle Scholar
  8. McCarthy SW, Scolyer RA, Palmer AA (2004) Desmoplastic melanoma: a diagnostic trap for the unwary. Pathology 36(5):445–451.  https://doi.org/10.1080/00313020412331285336CrossRefPubMedGoogle Scholar
  9. Murali R, Loughman NT, McKenzie PR, Watson GF, Thompson JF, Scolyer RA (2008) Cytologic features of metastatic and recurrent melanoma in patients with primary cutaneous desmoplastic melanoma. Am J Clin Pathol 130:715–723.  https://doi.org/10.1309/AJCPG4QZHLWFXMFJCrossRefPubMedGoogle Scholar
  10. Murali R, Shaw HM, Lai K, McCarthy SW, Quinn MJ, Stretch JR, Thompson JF, Scolyer RA (2010) Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer 116:4130–4138.  https://doi.org/10.1002/cncr.25148CrossRefPubMedGoogle Scholar
  11. Murali R, Zannino D, Synnott M, McCarthy SW, Thompson JF, Scolyer RA (2011) Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathology 58:886–895.  https://doi.org/10.1111/j.1365-2559.2011.03808.xCrossRefPubMedGoogle Scholar
  12. Oakley A (2017) Desmoplastic melanoma. In: DermNet NZ. Available via https://www.dermnetnz.org/topics/desmoplastic-melanoma. Accessed 17 Oct 2018
  13. Scolyer RA, Thompson JF (2005) Desmoplastic melanoma: a heterogeneous entity in which subclassification as “Pure” or “Mixed” may have important prognostic significance. Ann Surg Oncol 12(3): 197–199.  https://doi.org/10.1245/ASO.2005.12.914CrossRefPubMedGoogle Scholar
  14. Varey AHR, Goumas C, Hong AM, Mann GJ, Fogarty GB, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Lee KJ, Quinn MJ, Thompson JF, Scolyer RA (2017) Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. Mod Pathol 30(11):1538–1550.  https://doi.org/10.1038/modpathol.2017.76CrossRefPubMedGoogle Scholar
  15. Yeh I, McCalmont TH (2011) Distinguishing neurofibroma from desmoplastic melanoma: the value of the CD34 fingerprint. J Cutan Pathol 38(8):625–630.  https://doi.org/10.1111/j.1600-0560.2011.01700.xCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Teresa A. Bailey
    • 3
  • John F. Thompson
    • 3
  • Richard A. Scolyer
    • 1
    • 2
    • 3
    Email author
  1. 1.Tissue Pathology and Diagnostic OncologyRoyal Prince Alfred HospitalCamperdownAustralia
  2. 2.Sydney Medical SchoolThe University of SydneySydneyAustralia
  3. 3.Melanoma Institute AustraliaThe University of SydneySydneyAustralia

Section editors and affiliations

  • Boris C. Bastian
    • 1
  • Hensin Tsao
    • 2
    • 3
  1. 1.Departments of Dermatology and Pathology, Helen Diller Family Comprehensive Cancer CenterUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.AuburndaleUSA
  3. 3.Harvard-MIT Health Sciences and TechnologyCambridgeUSA

Personalised recommendations